|
[1] CORNBERG M,WONG VW,LOCARNINI S,et al. The role of quantitative hepatitis B surface antigen revisited[J]. J Hepatol,2017,66(2):398-411.
|
|
[2] COFFIN CS,ZHOU K,TERRAULT NA. New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection[J]. Gastroenterology,2019,156(2):355-368. e3.
|
|
[3] LIU J,YANG HI,LEE MH,et al. Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression[J]. Hepatology,2016,64(2):381-389.
|
|
[4] YU DM,LI XH,MOM V,et al. N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape[J]. J Hepatol,2014,60(3):515-522.
|
|
[5] WARNER N,LOCARNINI S. The antiviral drug selected hepatitis B virus rt A181T/s W172*mutant has a dominant negative secretion defect and alters the typical profile of viral rebound[J]. Hepatology,2008,48(1):88-98.
|
|
[6] CHAN HL,WONG VW,TSE AM,et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response[J]. Clin Gastroenterol Hepatol,2007,5(12):1462-1468.
|
|
[7] CHAN HL,WONG VW,WONG GL,et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B[J]. Hepatology,2010,52(4):1232-1241.
|
|
[8] NGUYEN T,THOMPSON AJ,BOWDEN S,et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B:A perspective on Asia[J]. J Hepatol,2010,52(4):508-513.
|
|
[9] THOMPSON AJ,NGUYEN T,ISER D,et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers:Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers[J]. Hepatology,2010,51(6):1933-1944.
|
|
[10] FATTOVICH G,OLIVARI N,PASINO M,et al. Long-term outcome of chronic hepatitis B in Caucasian patients:Mortality after 25 years[J]. Gut,2008,57(1):84-90.
|
|
[11] BROUWER WP,CHAN HL,BRUNETTO MR,et al. Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up[J]. Clin Gastroenterol Hepatol,2016,14(10):1481-1489. e5.
|
|
[12] BRUNETTO MR,OLIVERI F,COLOMBATTO P,et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers[J]. Gastroenterology,2010,139(2):483-490.
|
|
[13] SALI S,SHARAFI H,ALAVIAN SH,et al. Can serum level of HBsAg differentiate HBe Ag-negative chronic hepatitis B from inactive carrier state?[J]. Diagn Microbiol Infect Dis,2015,82(2):114-119.
|
|
[14] World Health Organization. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[R].Geneva:WHO,2015.
|
|
[15] SETO WK,WONG DK,FUNG J,et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B[J]. PLo S One,2012,7(8):e43087.
|
|
[16] MARTINOT-PEIGNOUX M,CARVALHO-FILHO R,LAPALUS M,et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-nave,e antigenpositive patients[J]. J Hepatol,2013,58(6):1089-1095
|
|
[17] MARCELLIN P,MARTINOT-PEIGNOUX M,ASSELAH T,et al. Serum levels of hepatitis B surface antigen predict severity of fibrosis in patients with e antigen-positive chronic hepatitis B[J]. Clin Gastroenterol Hepatol,2015,13(8):1532-1539. e1.
|
|
[18] LIANG LB,ZHU X,YAN LB,et al. Serum hepatitis B surface antigen titer and transient elastography in screening for insignificant fibrosis in HBe Ag-positive chronic hepatitis B patients[J]. Ther Clin Risk Manag,2015,11:229-235.
|
|
[19] XUN YH,ZANG GQ,GUO JC,et al. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers[J]. J Gastroenterol Hepatol,2013,28(11):1746-1755.
|
|
[20] JANSSEN HL,KERHOF-LOS CJ,HEIJTINK RA,et al. Measurement of HBs Ag to monitor hepatitis B viral replication in patients on alpha-interferon therapy[J]. Antiviral Res,1994,23(3-4):251-257.
|
|
[21] MARTINOT-PEIGNOUX M,ASSELAH T,MARCELLIN P. HBs Ag quantification to optimize treatment monitoring in chronic hepatitis B patients[J]. Liver Int,2015,35(Suppl 1):82-90.
|
|
[22] SONNEVELD MJ,HANSEN BE,PIRATVISUTH T,et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels[J]. Hepatology,2013,58(3):872-880.
|
|
[23] MOUCARI R,MACKIEWICZ V,LADA O,et al. Early serum HBs Ag drop:A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBe Ag-negative patients[J].Hepatology,2009,49(4):1151-1157.
|
|
[24] MARCELLIN P,BONINO F,YURDAYDIN C,et al. Hepatitis B surface antigen levels:Association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J]. Hepatol Int,2013,7(1):88-97.
|
|
[25] PAVLOVIC V,YANG L,CHAN HL,et al. Peginterferon alfa-2a(40 kD)stopping rules in chronic hepatitis B:A systematic review and meta-analysis of individual participant data[J].Antivir Ther,2019,24(2):133-140.
|
|
[26] CHEVALIEZ S,HZODE C,BAHRAMI S,et al. Long-term hepatitis B surface antigen(HBs Ag)kinetics during nucleoside/nucleotide analogue therapy:Finite treatment duration unlikely[J]. J Hepatol,2013,58(4):676-683.
|
|
[27] KIM WR,BERG T,ASSELAH T,et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol,2016,64(4):773-780.
|
|
[28] WURSTHORN K,JUNG M,RIVA A,et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients[J]. Hepatology,2010,52(5):1611-1620.
|
|
[29] HEATHCOTE EJ,MARCELLIN P,BUTI M,et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J]. Gastroenterology,2011,140(1):132-143.
|
|
[30] ZOUTENDIJK R,ZAAIJER HL,de VRIES-SLUIJS TE,et al.Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV[J]. J Infect Dis,2012,206(6):974-980.
|
|
[31] HOSAKA T,SUZUKI F,KOBAYASHI M,et al. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B:Results from a nineyear longitudinal study[J]. J Gastroenterol,2013,48(8):930-941.
|
|
[32] SETO WK,WONG DK,FUNG J,et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy[J]. Hepatology,2013,58(3):923-931.
|
|
[33] HADZIYANNIS E,LARAS A. Viral biomarkers in chronic HBe Ag negative HBV infection[J]. Genes(Basel),2018,9(10). pii:E469.
|
|
[34] BROQUETAS T,GARCIA-RETORTILLO M,HERNANDEZ JJ,et al. Quantification of HBs Ag to predict low levels and seroclearance in HBe Ag-negative patients receiving nucleos(t)ide analogues[J]. PLo S One,2017,12(11):e0188303.
|
|
[35] GRAMENZI A,LOGGI E,MICCO L,et al. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients[J]. J Viral Hepat,2011,18(10):e468-e474.
|
|
[36] SU CW,WU CY,HUNG HH,et al. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy[J]. J Gastroenterol Hepatol,2013,28(12):1849-1858.
|
|
[37] TERRAULT NA,LOK ASF,McMAHON BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.
|
|
[38] SARIN SK,KUMAR M,LAU GK. Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015 update[J]. Hepatol Int,2016,10(1):1-98.
|
|
[39] QIU YW,HUANG LH,YANG WL,et al. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients[J]. Int J Infect Dis,2016,43:43-48.
|
|
[40] WANG CC,TSENG KC,HSIEH TY,et al. Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg[J]. Am J Gastroenterol,2016,111(9):1286-1294.
|
DownLoad: